Full-Time
Development Manager
Posted on 7/23/2026
The ALS Association
201-500 employees
Advances ALS research and supports patients
Compensation Overview
$49.4k - $59.2k/yr
Kansas City, MO, USA
Remote
Remote within the Kansas City metropolitan area, with frequent territory travel and occasional overnight travel.
Bachelor's
 Business & Strategy (2) |
|---|
| , |
Get referred to The ALS Association
See people who can refer or advise you
- A bachelor's degree and at least 2 years of professional experience.
- Ability to interface with all levels of staff and volunteers and develop, maintain, and effectively utilize relationships.
- Demonstrated proficiency with Microsoft Word, Excel, and PowerPoint in a Windows environment.
- Ability to quickly learn, use, and train staff in a donor database such as Salesforce.
- Proficiency with video conferencing software.
- Ability to work evening and weekend hours for assigned events.
- An insured driver's license and access to an insured vehicle, as frequent travel throughout the territory may be required.
- Ability to stand for 6 hours daily during events and work varied hours, including early morning and late-night activity.
- Implement a comprehensive plan to meet an income portfolio goal of at least $450,000, including a golf tournament and a gala.
- Recruit, steward, and retain honorary chairs, event committee chairs, and committee members, and build strong relationships with community partners in collaboration with the Director of Development.
- Conduct face-to-face meetings and phone and email communication with event sponsors and donors, and ensure sponsorship benefits are executed according to a detailed sponsorship plan.
- Work with Marketing to develop event communication plans and coordinate the printing and distribution of event promotional materials.
- Ensure the integration of Association standards and guidelines.
- Analyze event performance weekly with the Development Director to support growth in future monetary totals and attendance.
- Adhere to event budgets, reconcile budgets to actuals, and provide event projections.
- Work as an integral part of the Territory team and support the Managing Director, Director of Development, and team members as needed.
- Attend events, committee and staff meetings, and territory-wide activities as assigned, including activities that may require overnight travel.
- Collaborate with Programs and Development departments to support and grow the effectiveness and efficiency of fundraising and mission activities.
- Perform other duties as assigned in support of mission and fundraising goals.
- Experience managing community fundraising, with an emphasis on strategic planning, financial management, volunteer management, and team building.
The ALS Association is a national nonprofit organization dedicated to fighting ALS on multiple fronts. It leads global research efforts, provides assistance to people with ALS through a nationwide network, coordinates multidisciplinary care via certified clinical care centers, and builds government partnerships to advocate for policies and funding. Its programs include funding and guiding research, offering patient and caregiver support, coordinating clinical care to ensure access to specialized services, and advocating for public policy and resources. This approach is distinct because it combines research leadership, direct services, and policy advocacy under one umbrella, with a nationwide network and dedicated ALS Nexus platform to connect patients, researchers, and clinicians. The goal is to discover new treatments and a cure for ALS while improving quality of life and expanding access to care for those affected.
Company Size
201-500
Company Stage
N/A
Total Funding
N/A
Headquarters
N/A
Founded
1985
Get referred to The ALS Association
See people who can refer or advise you
Simplify's Take
What believers are saying
- April 7, 2026, ACT for ALS reauthorization push protects a $39 million grant portfolio.
- May 7, 2026, $3 million clinic awards expand care in Hawaii, Alaska, Kansas.
- October 2025 ALS Focus dashboard deepens researcher adoption with 4,000-plus participants and free access.
What critics are saying
- January 2026 chapter lawsuit over restructuring threatens affiliate network and fundraising control.
- Workforce fell 15.8% from 2023 to March 2026, signaling internal strain.
- ACT for ALS programs expire in 2026, jeopardizing treatment access and research momentum.
What makes The ALS Association unique
- Largest ALS nonprofit, combining research funding, care delivery, and advocacy nationwide.
- 2026 ALS Focus dashboard turns community data into open research and policy intelligence.
- Hoffman clinic grants fund certified ALS centers in underserved states through 2027.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Company Match
Disability Insurance
Life Insurance
Wellness Program
Paid Vacation
Paid Holidays
Company News
NRG Therapeutics presents data on lead clinical asset NRG5051 confirming novel disease-modifying approach to ALS. * 2 hrs ago * Poster presentation at the ALS Association's ALS Nexus conference, August 23-26 * Disclosed that NRG5051 acts by inhibiting the mPTP through a novel NLRX1-mediated mechanism of action * Data showed that NRG5051 displays profound anti-inflammatory and neuroprotective effects in ALS mouse models STEVENAGE, United Kingdom, Aug. 24, 2026 (GLOBE NEWSWIRE) - NRG Therapeutics Ltd. ("NRG"), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in neurodegenerative diseases, today presented a poster on preclinical and mechanistic data of its lead clinical asset NRG5051 which is being developed as a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), and Parkinson's. In the poster NRG has disclosed that NRG5051, a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acts through a novel NLRX1-mediated mechanism of action. The scientists at NRG and their collaborators at WEHI are among the first to demonstrate that NLRX1 is essential for mPTP opening, establishing it as a key component or regulator of pore function. NLRX1 belongs to the NOD-like receptor family, a group of proteins that sense cellular stress and regulate immune responses. NLRX1 is unique within this family in being localized to the mitochondria. The mPTP is a key inner mitochondrial membrane channel implicated in the toxic effects of misfolded TDP43, which accumulates in mitochondria and triggers energetic failure and a damaging interferon response. Data presented, from research part funded by the ALS Association and Innovate UK, confirmed that NRG5051 displays profound anti-inflammatory and neuroprotective effects in acute NLS-TDP43 ALS mouse models, including reduced plasma neurofilament light (NfL) chain, a translatable fluid biomarker of neuronal damage. NRG5051 is currently in a Phase 1 randomized, double-blind clinical trial to assess safety, tolerability and pharmacokinetic parameters in healthy volunteers. Dosing in ALS patients is scheduled for later this year which will inform dose selection for future Phase 2 proof-of-concept trials in ALS patients planned for 2027. NRG Therapeutics' co-founder and CEO Neil Miller said, "Alongside advancing NRG5051 through preclinical studies and now into human clinical trials, we are pleased to have unravelled its novel mode of action in modulating the mPTP. Prevention of mPTP opening, via NLRX1, restores mitochondrial integrity and protects the function of vulnerable neurons. NRG5051 has the potential to be a truly disease-modifying medicine, offering a major step forward in our goal to slow or prevent the progression of ALS and other neurodegenerative diseases." ALS is a rare, rapidly progressing neurodegenerative disease with high unmet medical need. Despite recent success in treating patients with the very rare SOD-1 genetic form of ALS, the majority (90%) of patients with sporadic disease remain poorly treated by existing medicines. Media enquiries (for NRG Therapeutics) NRG Therapeutics is a clinical stage neuroscience company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), and Parkinson's. The Company's pipeline of first-in-class small molecules is based on inhibiting the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action. Inhibition of the mPTP has been shown to protect neurons, reduce neuroinflammation and improve motor function in preclinical disease models. Its lead clinical asset, NRG5051, is currently in a Phase 1 clinical trial. Based at the Stevenage Bioscience Catalyst (SBC), UK, NRG Therapeutics is a private company with equity investment from Brandon Capital, British Business Bank, Criteria Bio Ventures, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Omega Funds and Parkinson's UK. The company has also received awards from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation, Target ALS and The ALS Association to support its innovative R&D programmes.
The 2026 Walk to Defeat ALS Nashville returns to music city on October 3 at Nissan Stadium. Home " News " The 2026 Walk to Defeat ALS Nashville returns to music city on October 3 at Nissan Stadium. Community Invited to Unite in the Fight Against ALS at Nashville's Largest ALS Awareness and Fundraising Event NASHVILLE, Tenn. - The ALS Association is proud to announce the return of the 2026 Walk to Defeat ALS Nashville, presented by Beaman Toyota, on Saturday, October 3, 2026, at Nissan Stadium - Parking Lot H. The annual event will bring together individuals living with ALS, caregivers, families, volunteers, sponsors, and community members from across Middle Tennessee to raise awareness and critical funds in the fight against ALS. The Walk to Defeat ALS Nashville celebrates the strength and resilience of the ALS community while providing participants with an opportunity to honor loved ones, remember those lost to the disease, and stand together in pursuit of a world without ALS. Today, The ALS Association is actively serving more than 330 individuals living with ALS across Tennessee through comprehensive Care Services, including support groups, durable medical equipment and single-use item programs, care consultations, advocacy efforts, and investments in groundbreaking research. As the number of families diagnosed with ALS continues to grow, community support has never been more important. "Every step taken at the Walk to Defeat ALS represents hope for families facing this devastating disease," said Cody Filbert, Development Manager for The ALS Association. "While research is bringing us closer to effective treatments and ultimately a cure, families need support today. Funds raised through the Walk directly help provide critical care services while also advancing research and advocating for policies that improve the lives of those living with ALS." Participants of all ages and abilities are encouraged to register as individuals or create a Walk Team with family, friends, coworkers, schools, faith communities, or civic organizations. Local businesses are also invited to join the movement by becoming event sponsors, forming corporate Walk Teams, or volunteering on Walk Day. The event will feature an inspiring opening ceremony, a one-mile accessible walk, family- friendly activities, sponsor exhibits, food, entertainment, and opportunities to connect with the local ALS community. Event Details * Event: 2026 Walk to Defeat ALS Nashville * Date: Saturday, October 3, 2026 * Location: Nissan Stadium - Parking Lot H * Presenting Sponsor: Beaman Toyota * Registration: Opens at 10:30 a.m. * Opening Ceremony: 11:30 a.m. * Walk Begins: 11:45 a.m. Registration is free, and participants are encouraged to fundraise in support of The ALS Association's mission to discover treatments and a cure for ALS while serving, advocating for, and empowering people affected by the disease. About The ALS Association The ALS Association is the largest philanthropic funder of ALS research in the world and is committed to making ALS a livable disease while advancing global research toward effective treatments and a cure. Through comprehensive Care Services, advocacy, and research, The ALS Association supports individuals living with ALS and their families every step of the way.
Statement from the ALS Association on Chris Johnson's ALS Diagnosis. Arlington, Va. (June 29, 2026) - We are deeply moved by the courage Chris Johnson has shown in sharing his ALS diagnosis with the world. We stand with Chris, his wife Brittany, and their family as they navigate this incredibly difficult journey. "I still think the same. I still dream. I still love my family. My body just doesn't cooperate." Chris's words capture something we hear from so many people living with ALS. We are inspired by his determination to fight, and by his commitment to using his platform to raise awareness for the ALS community. What people need to know about ALS: * ALS is a fatal neurodegenerative disease that gradually takes away a person's ability to walk, speak, swallow, and eventually breathe. It affects the motor neurons in the brain and spinal cord that control voluntary movement. As those neurons deteriorate and die, the brain loses its ability to initiate and control muscle movement. * ALS does not discriminate. As Chris noted, his case is sporadic ALS - meaning it occurred with no family history. About 90% of all ALS cases are sporadic. * Every 90 minutes, someone in the United States is diagnosed with ALS - and someone loses their battle with it. * The ALS Association has a strategic plan to make ALS livable and cure it. To get there, we need to accelerate research, optimize current treatments and care, and reduce the harms of ALS. * ALS can be difficult to diagnose. There is no single test that confirms ALS. Because its early symptoms - muscle weakness, slurred speech, difficulty gripping - can resemble other conditions, people often see multiple specialists before receiving a confirmed diagnosis. This delay can mean lost time for treatment and support, which is why the ALS Association developed the thinkALS tool to help clinicians identify and refer patients to ALS specialists sooner. * There is currently no cure for ALS, and it is fatal. The typical life expectancy following a diagnosis is typically two to five years, though every journey is unique. * Research is making promising advancements and there is real reason for hope. We invested in early antisense technology which led to development and FDA approval to Qalsody (tofersen), the first-ever gene-targeted therapy for ALS. There is evidence that Qalsody(R) may not just slow disease progression, but in some cases help reverse some of the lost function, something that scientists did not think possible. * Chris has said he is participating in a clinical trial, reflecting the growing pipeline of promising treatments the ALS Association is proud to help fund. We are committed to accelerating the path from scientific discovery to treatments that reach every person living with ALS. Our mission - and how you can help. The ALS Association's mission is to make ALS livable and cure it. Here is how you can make a difference: * Learn more about ALS and share Chris's story * Donate to ALS research * If you or a loved one has been diagnosed, contact us. The ALS Association offers care services, support groups, and connections to certified treatment centers across the country. * Call our helpline at 1-800-782-4747 or visit ALS.org To Chris: thank you for choosing to fight - not just for yourself, but for the tens of thousands of Americans living with ALS today. We are honored to walk this road alongside you. About the ALS Association The ALS Association is the largest ALS organization in the world. The ALS Association funds global research collaborations, assists people with ALS and their families through its nationwide network of care and certified clinical care centers, and advocates for better public policies for people with ALS. The mission of the ALS Association is to make ALS livable and cure it. For more information about the ALS Association, visit our website at www.als.org. About ALS Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. The disease is always fatal, usually within five years of diagnosis. Few treatment options exist, resulting in a high unmet need for new therapies to address functional deficits and disease progression. Manager, Communications June 29, 2026 Article Topic ALS Mission ALS Awareness
South Florida woman turns ALS diagnosis into mission to inspire others to fight. By Najahe Sherman CBS News Miami June 23, 2026 7:20 PM Gift Article Surrounded by family, friends and supporters, this year's Walk to Defeat ALS champion, Lourdes Machado, was shining with hope. Diagnosed with ALS in May 2025, she has turned her journey into a mission to raise awareness and inspire others in the fight against the disease. "Obviously, there's no cure, and that's why we're walking," Machado said. "We're walking so no one else has to go through this again, and so I can spend more time with my daughter and be there for her." By her side through every challenge has been her mother, Marianela Perez, serving as both caregiver and unwavering source of strength. When she first learned of her daughter's diagnosis, Perez said she wanted her daughter to know she was not alone. "I wanted to say I love you a lot and I'm going to be here for you and here to support you," Perez said. "And I've done it for the last year, and I will continue to do it. I'm very proud of her. Very proud." The ALS Association is helping families like Machado's while also investing in groundbreaking research through its partnership with the University of Miami. Researchers are working to unlock new treatments. Dr. Nathan Carberry, an assistant professor of neurology at the University of Miami, said scientists are seeing encouraging progress in genetic treatments that have improved patients' strength. A development that was once thought impossible. "I liken it to the moon landing, where we're really seeing, finally, a true impact on a neurodegenerative disease, which is really powerful," Carberry said. For families facing ALS, breakthroughs like these are delivering something that once felt out of reach - hope. The money raised through the Walk to Defeat ALS helps families access resources, support and care. The organization welcomes support year-round. This report was produced by Miami Herald news partner CBS News Miami.
The ALS Association has awarded $3 million through its Hoffman ALS Clinic Awards Programme to expand access to multidisciplinary ALS care in underserved American communities. Currently, only around half of registered people living with ALS receive coordinated team-based care, which has been proven to extend survival and improve quality of life. The grants, funded by the late Hugh Hoffman's historic $58 million gift, will support seven clinics across underserved regions including Hawaii, Alaska, Northwest Indiana, Central Texas, rural Kansas and Southern New Jersey. Awards range from $360,000 to $900,000 over three years. Recipients will establish new ALS clinics or expand existing ones, adding clinic days, enhancing telehealth services and reducing financial barriers. The initiative aims to close the care gap for patients in rural and geographically isolated areas.